Balyasny Asset Management
TEVA icon

Balyasny Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Balyasny Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,613
Closed -$440K – 3339
2025
Q1 		$440K Sell
28,613
-802,626
-97% -$14.3M ﹤0.01% 2319
2024
Q4 		$18.3M Sell
831,239
-1,456,771
-64% -$26.5M 0.03% 707
2024
Q3 		$41.2M Sell
2,288,010
-1,454,959
-39% -$25.5M 0.07% 371
2024
Q2 		$60.8M Buy
3,742,969
+620,971
+20% +$9.56M 0.11% 244
2024
Q1 		$44.1M Buy
+3,121,998
New +$39.4M 0.08% 340
2023
Q4 		– Sell
-559,518
Closed -$5.71M – 2897
2023
Q3 		$5.71M Buy
+559,518
New +$5.21M 0.01% 1057
2023
Q2 		– Sell
-1,888,903
Closed -$16.7M – 2778
2023
Q1 		$16.7M Buy
1,888,903
+85,363
+5% +$844K 0.04% 582
2022
Q4 		$16.4M Buy
+1,803,540
New +$15.7M 0.05% 557
2022
Q3 		– Sell
-2,639,446
Closed -$19.8M – 3260
2022
Q2 		$19.8M Buy
2,639,446
+1,735,919
+192% +$15.1M 0.06% 423
2022
Q1 		$8.48M Buy
903,527
+883,783
+4,476% +$7.38M 0.03% 750
2021
Q4 		$158K Buy
+19,744
New +$178K ﹤0.01% 1898
2019
Q2 		– Sell
-1,596,027
Closed -$25M – 1724
2019
Q1 		$25M Buy
1,596,027
+813,862
+104% +$14.4M 0.17% 181
2018
Q4 		$12.1M Sell
782,165
-844,463
-52% -$17.3M 0.09% 309
2018
Q3 		$35M Buy
1,626,628
+670,720
+70% +$15.6M 0.16% 175
2018
Q2 		$23.2M Sell
955,908
-624,548
-40% -$12.7M 0.11% 274
2018
Q1 		$27M Buy
1,580,456
+1,024,166
+184% +$20M 0.11% 250
2017
Q4 		$10.5M Sell
556,290
-1,089,636
-66% -$16.4M 0.03% 622
2017
Q3 		$29M Buy
+1,645,926
New +$37M 0.11% 239
2016
Q4 		– Sell
-134,803
Closed -$5.38M – 1482
2016
Q3 		$6.2M Buy
+134,803
New +$7.03M 0.04% 467
2016
Q2 		– Sell
-195,732
Closed -$10.4M – 1442
2016
Q1 		$10.5M Sell
195,732
-3,194,576
-94% -$187M 0.06% 392
2015
Q4 		$223M Buy
3,390,308
+2,112,174
+165% +$131M 1.54% 1
2015
Q3 		$72.2M Sell
1,278,134
-62,829
-5% -$4.07M 0.53% 33
2015
Q2 		$79.3M Buy
1,340,963
+1,277,301
+2,006% +$78.8M 0.49% 38
2015
Q1 		$3.97M Sell
63,662
-633,782
-91% -$36.8M 0.03% 510
2014
Q4 		$40.1M Buy
697,444
+522,721
+299% +$29.1M 0.37% 61
2014
Q3 		$9.39M Sell
174,723
-216,491
-55% -$11.5M 0.07% 315
2014
Q2 		$20.5M Buy
391,214
+106,003
+37% +$5.42M 0.23% 93
2014
Q1 		$15.1M Buy
285,211
+144,811
+103% +$6.69M 0.17% 153
2013
Q4 		$5.63M Sell
140,400
-476,202
-77% -$18.8M 0.07% 294
2013
Q3 		$23.3M Sell
616,602
-186,411
-23% -$7.27M 0.31% 77
2013
Q2 		$31.5M Buy
+803,013
New +$31.3M 0.53% 36

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's TEVA Position: Q2 2025 in Review

Balyasny Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 28,613 shares — an estimated $440K sold.

Balyasny Asset Management first reported a position in TEVA in Q2 2013 and held it in 31 quarters. The position peaked at $223M in Q4 2015. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Balyasny Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 28,613 Teva Pharmaceuticals shares in Q2 2025, an estimated $440K.
  • Balyasny Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Balyasny Asset Management's Teva Pharmaceuticals position peaked at $223M in Q4 2015.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.